Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Gloria those assets are costing a fortune in maintenance. I loved AVCT. But when it was 67p. Popular Twitter folk sucked a lot into that one and made a fortune in the process. Also at least David didn't buy a house when the SP was pumped the the avct CEO did.
EU partners lined up.
Distribution partners already engaged.
Additional proactive parties have approached based on the characteristics of the test, namely the industry benchmark speed, the unique biosafety buffer, and the ease of use by non technicians.
You could buy a kit and start up your own testing company the sane day.
Yea it was definitely worked applebee. They could have taken it either way today after yesterday. They got some large orders to fill so had to panic a few out of their stock (level playing ground and all that). Went into NT so many on the offer as well.
Seems like a few sold out pending Boris' announcement. Not sure what people were expecting to hear. New variant still there and spreading, NHS still struggling and over run, emergency restrictions areas (ERA) all over the place.
MM's happy to take down to fill yet another order 689k - that was more than the average daily volume last week! On the volume it would be so easy to choke this all the way up like Novacyts move from 252p to 1260p in a couple of weeks if people held onto their stock for more than 20 minutes.
CE Marking:
People waiting for the CE mark like its a caveat should remember that on commercial products, the letters CE mean that the manufacturer or importer affirms the good's conformity with European health, safety, and environmental protection standards. It is not a quality indicator or a certification mark. Its a paper exercise, the product is proven - the CE Mark is a given!
Consolodating well and keeps coming back for the quick dips. This is how it usually moves given the number of shares in issue. MM's need to keep fishing to underline new highs. Predicting this to have a big big finish this week.
Given we have parties actively approaching for the first time ever, we may even see new order cycles transferred over to GDR. LFT's are such a bag of sh1£e by comparison, and as we know the government has done a bit of a U-Turn. Innova - the LFT - used across the country was found not to be suited for use outside a lab, and when doing so yields results of 54% (similar accuracy to a coin toss). Only 74% in a lab with a technician!
Proper regulated tests are a must, this ticks all the boxes and has set new benchmarks. Last RNS was stella.
Haters are going to keep hating but thats not how you invest, unless of course you are not invested.
So we know this has sent a new benchmark for tests as a whole, but these are the key points, must of which trump the competition:
Sets new benchmark in speed, accuracy and ease of use
Offers a step change in rapid molecular testing, delivering positive results as quickly as 7.5 minutes and negative results at 17 minutes = Fastest on market!
As well as being made available commercially in the European Union, the product is being provided for review and evaluation to a range of potential commercial partners who have ‘actively’ expressed interest in the product.
Isothermal Amplification = no need for the expensive thermocyclers which Traditional PCR’s use so absolutely perfect for
lower income countries ans well as developed markets.
The assay targets the ORF1ab and N genes of the SARS-CoV-2 genome, adding robustness against emerging SARS-CoV-2 variants which generally impact assays targeted against the S-gene (Spike protein).
Detects B.1.1.529 South African Omicron variant.
Clinical validation against the Thermo Fisher TaqPath COVID-19 RT-PCR test!
Offers several orders of magnitude improvement in sensitivity compared to antigen lateral flow devices.
The sensitivity and specificity of the assay on the entire cohort met the current requirements of the UK's MHRA Target Product Profile for a SARS-CoV-2 Point of Care molecular diagnostic test.
Me too but average is much much healthier now albeit it a little overexposed. Consider all the R&D cost and time aswell. Easier to be upbeat on positive sentiment but the MC is low in my opinion. Just need to keep an eye on cash burn but I'll worry about that a lot lot later.
Novacyt has done 100% in 10 days and GDR has done 35% since Wednesday. If they can get that CE through they might actually get it bang on for a change. Sentiment has flipped for now either way. ODX was floating between 50-80 mill on relatively little.
Quicker point of care needed for airports, care homes etc. Market is there and far less saturated for POC if this new team can seize the opportunity.
And it's seems that a negative BB doesn't account for much after all. Just depressing.
Good luck whatever your strategies. Personally I need this to go up so I can sell it for more than I paid ;)
Hi James. David has had dialogue with holders, however, he will likely direct your questions to Walbrook who in turn will direct you to a circular as they do not have the capacity or industry knowledge to answer questions in their client's field in the case of GDR. BUT, David did say in the presentation last week that if they can't answer then get them to direct the questions back to GDR. I expect that is what you will be doing. Hopefully Walbrook has had a slap on the wrist for being placid.
So not the onslaught people were expecting and some huge postitions being taken up to 500,000 today
POC deadline has been missed again as we all expected but they have finally realised where they sit in the pond - and that is not the US. Mobile POC tests are fast being developed by some of the largest diagnostic companies. With PCR's being less common, although still being used massively to confirm LFT's, there will be more demand on POC for more accurate results that LFT's can provide. Dissappointing they have missed their own deadline yet again but the opportunity is a massive one in this area. Localised demand for venues and services, airports etc will likely be the way forward as less people conduct voluntary self-testing at home, especially if things get bad over winter which all indicators are pointing to.
Market is extremely cautious here for good reason. AIHL test is a result of 3 years in the making and is a very good result for those affected by it's need. Trials came back 100% successful and the UK and EU are a big enough market for this and I expect it to be taken up in EU on the CE Mark in quick stead.
The playing field is still wide open for the mobile POC kit and if they get it finished the opportunity is there for the sales team who no doubt will be heavily incentified.
Past dealings are a concern but 19p and an £18m market cap with all the R&D paid for by pervious placings and shareholders does present value for people investing today with a similar risk as presented in December last year. CE Mark now takes just 2 weeks acording to todays RNS (still waiting on samples). We know the CE Mark for the AIHL went through very quickly post the NHS feedback revisions. A bit more informaton on the POC samples would have been nice but there you go (will pop that on the Investormeet questions for the presentation on Thursday).
Still confident a new board would give immediate value. This board should have aligned themselves following dire performance through salary reductions, reduced directors or payment in shares. The failed in this respect which is why they need to go - actually there is a ton of reasons why they need to go. Might be safer to wait for the CE Mark to come through before positioning but that will come at a premium imo.
Final clarity on Thursday but so far this is held up well againt price predictions mentioned today. Looking at this with fresh eyes would I invest today based on opportunity (which is what AIM is all about) - the answer is yes, with caution and scaling in. 3 million or 600% average volume traded in under 3 hours today and we are near flat. Thursdays presentation and Fridays finish will tell us more.